Canadian researchers are launching a pilot study testing deep transcranial magnetic stimulation (dTMS) in 30 adults aged 60-90 with mild neurocognitive disorder—cognitive decline that doesn't yet impair daily functioning. The protocol will test three FDA-approved coil configurations (H1, H4, H7) targeting brain regions like the prefrontal cortex and anterior cingulate over 20 sessions across six weeks. This represents a promising frontier in addressing the treatment gap for mild cognitive impairment, which affects millions globally and often progresses to dementia. Deep TMS can stimulate broader, deeper brain areas compared to standard techniques, potentially offering more comprehensive neural circuit modulation. The intervention's non-invasive nature makes it appealing for older adults who may not tolerate medications well. However, this remains early-stage research—the study primarily examines feasibility and safety rather than definitive therapeutic benefits. As a preprint protocol awaiting peer review, the methodology and eventual results require scientific validation. If successful, this approach could provide a much-needed therapeutic option for the growing population experiencing early cognitive decline, though larger randomized trials would be essential before clinical implementation.